Search

Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease.

… Thursday, January 14, 2021 Early CD4+ T cell reconstitution predicted non-relapsing mortality and overall survival (OS) in pediatric patients who received an allogeneic hematopoietic stem cell transplant (HCT) and developed acute graft-versus-host disease (GVHD), according to our research published recently

MSK experts believe that giving the targeted drug asciminib to patients with chronic myeloid leukemia at the beginning of their treatment offers them a better chance of being cured.

… Friday, January 17, 2025 When Aaron von Freter learned he had  chronic myeloid leukemia (CML) , he “felt like the room was spinning,” he remembers. “I thought I’d been served a death sentence.” Aaron was 45 years old and had no symptoms. His CML diagnosis came after standard bloodwork revealed an extremely

Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. Fellows are chosen based on excellence demonstrated by their thesis proposal examinations.

… Monday, October 10, 2011 Third-year students Oakley Olsen and Alison Spencer have been named Grayer Fellows. These fellowships were established by Mr. and Mrs. Jonathan Grayer. Mr. Grayer is a member of the Gerstner Sloan Kettering Board of Trustees and the former chairman and CEO of Kaplan, Inc., which

Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution.

… Wednesday, April 16, 2014 Summary Former leader of Memorial Sloan Kettering Paul Marks gives a compelling view of cancer research and treatment over the past 40 years in On the Cancer Frontier: One Man, One Disease, and a Medical Revolution . Paul Marks — who served as President and Chief Executive Officer

Memorial Sloan Kettering's Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan Kettering Institute's Grégoire Altan-Bonnet and Songhai Shi.

… Wednesday, July 1, 2009 Summary Memorial Sloan Kettering’s Boards of Overseers and Managers have announced the creation of the Bristol-Myers Squibb/James D. Robinson III Junior Faculty Chairs and have named the first two incumbents: Sloan Kettering Institute’s Grégoire Altan-Bonnet and Songhai Shi. Memorial

James Rothman, who receives this year’s Nobel Prize in Physiology or Medicine together with Randy Schekman and Thomas Südhof, conducted more than a decade of his seminal research at Memorial Sloan Kettering.

… Monday, October 14, 2013 Summary James Rothman, who receives this year’s Nobel Prize in Physiology or Medicine together with Randy Schekman and Thomas Südhof, conducted more than a decade of his seminal research at Memorial Sloan Kettering. Last week James E. Rothman, Randy W. Schekman, and Thomas C.

Meet Mary Wu, a patient financial services specialist at Memorial Sloan Kettering Westchester.

… Tuesday, May 17, 2022 Mary Wu remembers the 2012 Rose Parade like it was yesterday. The roar of the spectators lining Colorado Boulevard as each float came into view. The warmth of the New Year’s Day sun. Her perch atop the Donate Life Float . “I can’t put it into words,” says Mary, a patient financial

MSK researchers have found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer.

… Wednesday, July 18, 2018 Summary MSK-IMPACT™ has led to many important findings about cancer genomics. In a recent study, researchers found that a genetic state in tumors called whole-genome doubling is connected with worse outcomes for people with cancer. Healthy cells contain two copies of each gene

New research on an experimental drug provides hope for better responses to immunotherapy.

… Wednesday, November 9, 2016 Summary Despite the promise of immunotherapy for cancer, not everyone responds. Researchers at MSK are testing a new drug that can overcome a tumor’s resistance to immunotherapy. Highlights Many tumors contain immune-suppressive cells that make them resistant to immunotherapy

… Monday, January 5, 2026 Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments: Jason Lewis Elected as a Fellow of the National Academy of Inventors (NAI)   Jason Lewis Jason Lewis, PhD , Radiochemist, Emily Tow Chair in Oncology; Deputy Director, Sloan Kettering